- Home
- EDU vs ALKS Comparison
EDU vs ALKS Comparison
Compare EDU & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | ALKS |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.7B |
| IPO Year | 2006 | 2012 |
Fundamental Metrics
Financial Performance| Metric | EDU | ALKS |
|---|---|---|
| Price | $55.48 | $40.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 19 |
| Target Price | ★ $73.62 | $56.56 |
| AVG Volume (30 Days) | 406.4K | ★ 1.7M |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $16.58 | $23.57 |
| Revenue Next Year | $12.33 | $6.48 |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.25 | $27.00 |
| 52 Week High | $64.97 | $55.67 |
Technical Indicators
Market Signals| Indicator | EDU | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 31.74 |
| Support Level | $54.06 | $36.25 |
| Resistance Level | $56.57 | $51.25 |
| Average True Range (ATR) | 1.00 | 1.42 |
| MACD | -0.17 | -0.27 |
| Stochastic Oscillator | 33.50 | 15.22 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in livestreaming e-commerce.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.